
Stock·NASDAQ·Healthcare
IDEXX Laboratories, Inc. (IDXX)
- Market cap
- $53.28B
- P/E
- 45.57
- Dividend yield
- No dividend
- Street target
- $717.50median of 14 analysts
- 52-week range
- $500.61 $769.98
What moved IDEXX Laboratories, Inc. (IDXX)
Updated . Market figures as of November 20, 2026.
Was it the market or the company?
On November 20, 2026, IDXX fell 1.95%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.
The move was in line with the market. IDXX's one-year beta to SPY is 0.79, so SPY's -3.64% would on average have meant -2.86% for IDXX, close to what it did (0.9 percentage points less).
Over the last 20 sessions IDXX is up 20.67% against -9.23% for SPY, 29.9 percentage points ahead of it.
The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)
| That day | 5 sessions | 20 sessions | |
|---|---|---|---|
| IDXX | -1.95% | -3.98% | +20.67% |
| S&P 500 (SPY) | -3.64% | -8.56% | -9.23% |
| Nasdaq 100 (QQQ) | -5.67% | -10.51% | -13.62% |
| Health care sector (XLV) | -0.12% | -6.15% | -1.14% |
Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.
What changed since November 19, 2026
- CleaRank score: 70/100 on November 19, 2026, 66/100 on November 20, 2026 (still Buy).
IDXX stock today, November 22, 2026: price, news and analyst targets
As of November 20, 2026, IDEXX Laboratories, Inc. (IDXX) trades at $676.21. Wall Street's median 12-month price target is $717.50 across 14 analysts, 6.1% above the price. CleaRank rates it Buy with a score of 66/100.
IDEXX Laboratories (IDXX) reported third-quarter results on November 2, 2026, beating the analysts' EPS estimate by 8.09%, and the stock rose 21.85% in the first session after the report. The move has carried it to $676.21, which is 12.18% below its 52-week high of $769.98 but still 16.61% above its 50-day moving average. Analysts are broadly positive, with nine of 14 rating the stock Buy, and the stock sits near the median 12-month target of $717.50. The question for investors is whether the company's earnings momentum can keep the shares above their newly reset levels while the valuation remains well above the sector. Revenue grew 9.66% in the latest quarter compared with a year earlier, faster than the sector median of 8.1%. The stock has moved in a wide band since the report, and it closed the latest session down 1.95% on volume 29.4% above its average.
What the earnings beats have done to the stock
IDEXX has beaten the analysts' EPS estimate in all eight of the recent reports on the record, with the latest, on November 2, 2026, coming in at $4.01 against an estimate of $3.71. The stock rose 21.85% in the first session after that report, the largest move in the set. Beats have not always lifted the shares, though: two of the eight beats were followed by a lower price in the first session, and the February 2, 2026 beat was followed by a 4.60% decline.
Valuation is the main cost of the rally
The stock trades at a trailing P/E of 45.57, a premium to peers and 42.8% above the sector median of 31.9. Its price-to-sales ratio of 11.43 is far above the sector median of 3.4. Those multiples are supported by a 25.03% net profit margin, a 32.50% operating margin and a return on equity of 68.93%, against a sector median of 7.3%, so the premium reflects the quality of the earnings as well as their growth.
Analysts remain positive, with a few cautious voices
Of 14 analysts with a current rating, nine rate the stock buy or strong buy, four hold it and one sells it. Eight of the 14 ratings were buy three months ago, so the split has moved toward buy. Recent actions included Morgan Stanley keeping its Overweight rating on November 3, 2026, and UBS keeping its Neutral rating on the same day and again on October 27, 2026. The median target of $717.50 sits 6.1% above the price.
Insider sales have been large
Insiders sold $96.6 million of stock across 18 sales over the last 18 months and made no open-market purchases. Many insider sales are planned in advance or made to cover tax on vesting shares, so they say less about the outlook than purchases would, but the sustained selling is worth watching alongside a stock that has risen sharply.
CleaRank score 66/100 (Buy). 15 of 18 checks pass: trend 4 of 4, momentum 3 of 3, valuation and quality 2 of 4, analysts 3 of 3, track record 3 of 4.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality.
IDXX stock news
Strong third-quarter beat
·Earnings report
The November 2, 2026 report beat the EPS estimate by 8.09%, and the stock rose 21.85% in the next session. It is the event that drove the shares to their current level and reset expectations for the year.
Overweight rating kept by Morgan Stanley
·Morgan Stanley
Morgan Stanley kept its Overweight rating on November 3, 2026, one day after the earnings report. It signals continued support from a major brokerage after the results.
UBS keeps Neutral stance
·UBS
UBS kept its Neutral rating on November 3, 2026, after keeping the same rating on October 27, 2026. The stance shows a more cautious view that balances the positive ratings from other firms.
JP Morgan keeps Overweight
·JP Morgan
JP Morgan kept its Overweight rating on October 16, 2026. The earlier endorsement shows a positive view that predates the latest earnings beat.
Keybanc starts at Sector Weight
·Keybanc
Keybanc started coverage at Sector Weight on October 12, 2026. A neutral start from a new firm adds a view that is neither bullish nor bearish to the set of analyst opinions.
IDXX price target 2026
The base case is that IDEXX keeps its earnings momentum and the shares hold above the 20-day average near $659.68 and the 50-day average near $579.87. Analysts expect EPS to grow 14.9% this fiscal year to $15.02 and 12.4% next year to $16.89, which supports the case if those estimates are met. The median 12-month target of $717.50 sits 6.1% above the price, and the range runs from $470.00 to $810.00, so analysts see room for further gains but also a wide spread of views. The case would improve if the next quarterly report beats estimates again and the stock reclaims its 52-week high of $769.98. The case would weaken if the price closes below the 20-day average and the 50-day average starts to slip, or if a beat fails to lift the shares as it did in earlier reports. A P/E of 45.57, well above the sector median of 31.9, leaves little room for disappointment if growth slows.
Analyst targets and ratings
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 3, 2026 | Morgan Stanley | Maintains | Overweight |
| Nov 3, 2026 | UBS | Maintains | Neutral |
| Oct 27, 2026 | UBS | Maintains | Neutral |
| Oct 16, 2026 | JP Morgan | Maintains | Overweight |
| Oct 12, 2026 | Keybanc | Initiates | Sector Weight |
| Aug 11, 2026 | Barclays | Maintains | Overweight |
IDXX support and resistance levels
Support sits first at the 20-day exponential moving average of $659.68, which the price is now just above and which a fall would reach first. Below it, the 50-day simple moving average at $579.87 is the next level a decline would test, followed by the 200-day simple moving average at $573.48, which lies close to it and together forms a broad support zone. The 52-week low of $500.61 is the deepest support on the chart. Resistance is the 52-week high of $769.98, the only level above the price, and it is the level a rise would meet first.
| Level | What it is | Price | From the price |
|---|---|---|---|
| Resistance 1 | 52-week high | $769.98 | +13.9% |
| Price | November 20, 2026 | $676.21 | |
| Support 1 | 20-day exponential average | $659.68 | -2.4% |
| Support 2 | 50-day moving average | $579.87 | -14.2% |
| Support 3 | 200-day moving average | $573.48 | -15.2% |
| Support 4 | 52-week low | $500.61 | -26.0% |
Technical indicators
IDXX technical analysis in depth
Volatility, momentum, trend strength and the price levels that matter for IDXX, calculated by CleaRank from daily bars to November 20, 2026.
Volatility
On the 20-day Bollinger Bands (2 standard deviations) the bands run from $547.19 to $770.20 around a middle of $658.69, and IDXX's close of $676.21 sits inside the bands, away from both edges.
Band width is 33.9% of the price, in the middle of its range over the last 120 sessions.
The 14-day average true range is $22.60, or 3.3% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 5.0% from the close.
Momentum and volume
The 14-day stochastic reads 41 (signal line 69): the close is in the middle of its two-week range.
The MACD line (12, 26) is 34.81 against a signal line (9) of 38.07, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 1 session ago.
Volume in the latest session was 0.9 times its 20-day average.
Trend strength
The 14-day ADX is 35: a trending market, with buyers in control (+DI 27, -DI 18).
On the weekly chart the 10-week average ($579.57) is above the 40-week average ($569.78), a rising longer-term trend, and the weekly RSI is 66.
Key levels
The nearest resistance from the price history is $720.07 (+6.5%): the price turned here 2 times, most recently on November 4, 2026.
The nearest support is $659.87 (-2.4%): the price turned here 3 times, most recently on February 26, 2026.
The largest swing of the last 120 sessions ran up from $500.61 (September 11, 2026) to $713.74 (November 4, 2026); the nearest Fibonacci retracement to the price is the 23.6% level at $663.44.
Classic pivot points for the next session, from November 20, 2026: pivot $681.94, resistance $691.16 and $706.11, support $666.99 and $657.77.
| Level | Price | From the price | What it is |
|---|---|---|---|
| Upper Bollinger Band | $770.20 | +13.9% | 20-day average + 2 standard deviations |
| Resistance (swing high) | $720.07 | +6.5% | the price turned here 2 times, most recently on November 4, 2026 |
| Pivot R2 (classic) | $706.11 | +4.4% | next-session level |
| Pivot R1 (Fibonacci) | $691.17 | +2.2% | 38.2% of the last range above the pivot |
| Pivot R1 (classic) | $691.16 | +2.2% | next-session level |
| Pivot point | $681.94 | +0.8% | average of the last high, low and close |
| Price | $676.21 | close, November 20, 2026 | |
| Pivot S1 (Fibonacci) | $672.71 | -0.5% | 38.2% of the last range below the pivot |
| Pivot S1 (classic) | $666.99 | -1.4% | next-session level |
| Fibonacci 23.6% | $663.44 | -1.9% | retracement of the rise from $500.61 to $713.74 |
| Support (swing low) | $659.87 | -2.4% | the price turned here 3 times, most recently on February 26, 2026 |
| Pivot S2 (classic) | $657.77 | -2.7% | next-session level |
| Fibonacci 38.2% | $632.32 | -6.5% | retracement of the rise from $500.61 to $713.74 |
| Support (swing low) | $615.08 | -9.0% | the price turned here 5 times, most recently on August 4, 2026 |
| Fibonacci 50.0% | $607.17 | -10.2% | retracement of the rise from $500.61 to $713.74 |
| Fibonacci 61.8% | $582.03 | -13.9% | retracement of the rise from $500.61 to $713.74 |
| Support (swing low) | $581.21 | -14.0% | the price turned here 6 times, most recently on July 16, 2026 |
| Lower Bollinger Band | $547.19 | -19.1% | 20-day average - 2 standard deviations |
| Fibonacci 78.6% | $546.22 | -19.2% | retracement of the rise from $500.61 to $713.74 |
Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.
IDXX stock price and trading
IDXX share price
IDXX fundamentals and valuation
Key statistics
IDXX against the Healthcare sector
Price to earnings vs sector: IDXX trades at a significant premium to sector peers (+43% against the sector median P/E). Investors are paying more for each dollar of earnings than for the typical stock in the sector.
Return vs XLV: Since Jun 11, 2025, IDXX has gained 29.0% against a gain of 30.6% for XLV.
Performance against XLV
Revenue and earnings
Revenue growth: Revenue grew 10.4% in FY2025 to $4.3B, from $3.9B a year earlier.
Profit margin: The net margin was 24.6% in FY2025, up from 22.8% the year before.
Profitable: IDXX earned $1.1B in FY2025.
Earnings reality check
Earnings record: IDXX beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 2 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Nov 2, 2026before open | $3.71 | $4.01 | +8.09% | +21.85% | +22.65% |
| Aug 4, 2026before open | $3.93 | $4.27 | +8.65% | +3.57% | +4.92% |
| May 5, 2026before open | $3.41 | $3.47 | +1.76% | -0.03% | -5.53% |
| Feb 2, 2026before open | $2.94 | $3.08 | +4.76% | -4.60% | -3.86% |
| Nov 3, 2025before open | $3.15 | $3.40 | +7.94% | +14.84% | +12.54% |
| Aug 4, 2025before open | $3.30 | $3.63 | +10.00% | +27.49% | +22.88% |
| May 1, 2025before open | $2.84 | $2.96 | +4.23% | +8.95% | +12.47% |
| Feb 3, 2025before open | $2.40 | $2.62 | +9.17% | +11.13% | +8.94% |
IDXX price history and drawdowns
Risk profile
Worst falls and recoveries
Growth of $10,000
Against the market: IDXX beat the S&P 500 over this period: $59,228 against $36,764.
A $10,000 investment in IDXX in December 2016 would be worth about $59,228 today, compared with about $36,764 for the same investment in the S&P 500 benchmark with its dividends reinvested.
IDXX stock price prediction 2030
IDXX Stock Price Prediction 2030: Simulated Scenarios
CleaRank's simulation projects a price near $992 for IDXX by 2030 in the base case, from $676 today (1.5x over 4 years). The 10th-percentile path ends near $422. These are outcomes of a Monte Carlo simulation run on IDXX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $485 | $744 | $1,141 | |
| 2028 | $448 | $819 | $1,499 | |
| 2029 | $430 | $901 | $1,889 | |
| 2030 | $422 | $992 | $2,331 |
IDXX insider trading
IDXX insider trading
Month by month
Net insider selling: No insider bought IDXX shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Jonathan Jay Mazelsky
Officer and Director
|
Sell | 25.1K | $17.7M |
| Nov 4, 2026 | Sharon E Underberg
General Counsel
|
Sell | 8.9K | $6.1M |
| Nov 4, 2026 | Daniel M Junius
Director
|
Sell | 1.2K | $844.9K |
| Nov 4, 2026 | Jonathan Jay Mazelsky
Officer and Director
|
Option | 25.1K | $4.5M |
| Nov 4, 2026 | Sharon E Underberg
General Counsel
|
Option | 8.9K | $2.6M |
| Oct 30, 2026 | Joseph L. Hooley
Director
|
Grant | 48 | $26.5K |
| Sep 4, 2026 | Lawrence D Kingsley
Director
|
Sell | 2.2K | $1.2M |
| Sep 4, 2026 | Lawrence D Kingsley
Director
|
Option | 2.2K | $251.5K |
| Aug 20, 2026 | Andrew Emerson
Chief Financial Officer
|
Option | 265 | $47.2K |
| Jul 30, 2026 | Joseph L. Hooley
Director
|
Grant | 49 | $27.4K |
IDXX stock forecast: questions people ask
IDXX Forecast: Frequently Asked Questions
What is the IDXX stock forecast?
What is the IDXX price target?
Is IDXX a buy or sell today?
How has IDXX performed over the past year?
How does IDXX's valuation compare with its sector?
Has IDXX beaten earnings estimates recently?
How these figures are computed, and where the data comes from: CleaRank methodology.